A Phase II Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms PANDORE
- 07 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Jan 2019 Planned End Date changed from 1 May 2019 to 1 Oct 2019.
- 02 Jan 2019 Planned primary completion date changed from 1 May 2019 to 1 Oct 2019.